TICKERNERD
Menu
AVTRAVTRHealthcare · Medical Instruments & Supplies

AVTR Stock Forecast: Avantor, Inc. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$15
−2.43% on the day

The 16 Wall Street analysts covering Avantor, Inc. hold a median 12-month price target of $14 — -4.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 8 Sept 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$10.1B
Ticker Nerd rank
80 / 100
Median analyst target
$14
Analysts covering
16
Revenue$1.7B+0.5% y/y
Operating income$121.8M
Net income$38.1M
Free cash flow$140.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.8%
1M
+9.5%
YTD
+29.8%
1Y
+16.0%
From 52W high
−4.6%
From 52W low
+100.8%
$7
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AVTR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Avantor, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
94
Issuance
94
Accruals
93
Momentum
65
Value
56
Volatility
53
Quality
42
Growth
39
Size
15

Revisions (94): Analysts have, on balance, been raising their forecasts.

Growth (39): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AVTR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVTR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$8$10$12$14$16$18$20Oct 25Jan 26Apr 26Jul 26AVTRHigh $19Median $14Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
3 Buy12 Hold1 Sell
Low $12Median $14High $19

The green dot is the last close — the median target sits −4.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Sept 2026UBSMaintainsNeutral$11 → $16
30 July 2026Evercore ISI GroupMaintainsIn-Line$11 → $14
30 July 2026Morgan StanleyMaintainsEqual-Weight$10 → $14
30 July 2026RBC CapitalMaintainsSector Perform$9.00 → $14
30 July 2026StifelMaintainsHold$8.00 → $15
30 July 2026Wells FargoMaintainsOverweight$14 → $16
8 July 2026CitigroupMaintainsNeutral$9.00 → $11
8 July 2026CitigroupMaintainsNeutral—
6 July 2026Evercore ISI GroupMaintainsIn-Line—
6 July 2026Evercore ISI GroupMaintainsIn-Line$8.00 → $11
26 June 2026BernsteinReinstatesMarket Perform$11
24 June 2026BarclaysMaintainsUnderweight—
2 June 2026Wolfe ResearchAssumesUnderperform$7.00
15 May 2026RBC CapitalReinstatesSector Perform$9.00
30 Apr 2026CitigroupMaintainsNeutral—
30 Apr 2026Evercore ISI GroupMaintainsIn-Line—
15 Apr 2026BarclaysMaintainsUnderweight—
6 Apr 2026Evercore ISI GroupMaintainsIn-Line—
6 Mar 2026BarclaysDowngradeUnderweight—
13 Feb 2026Wells FargoMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVTR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AVTR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, Avantor, Inc. returned +16.0% against +18.5% for the S&P 500, dividends included.

AVTR vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Oct 25Jan 26Apr 26Jul 26AVTRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AVTR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.0%
Analysts raising
15
Analysts cutting
0
Fundamentals

Avantor, Inc. (AVTR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
14.9×

Cheaper than 47% of US stocks

Price / sales
1.5×

Cheaper than 60% of US stocks

Price / book
1.8×

Cheaper than 50% of US stocks

EV / EBITDA
14.3×

Cheaper than 25% of US stocks

Growth & margins
Revenue growth (YoY)
0.5%

Higher than 28% of US stocks

Earnings growth (YoY)
−41.1%

Higher than 12% of US stocks

Gross margin
31.7%

Higher than 37% of US stocks

Operating margin
7.2%

Higher than 59% of US stocks

Net margin
−8.8%

Higher than 21% of US stocks

Returns & dividend
Return on equity
−9.7%

Higher than 36% of US stocks

Return on assets
2.7%

Higher than 63% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Avantor, Inc. (AVTR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Avantor, Inc. has a market value of $10.1B and an enterprise value of $13.5B.

  • Revenue in the twelve months to 30 June 2026: $6.6B. The latest quarter grew 0.5% year on year.

  • Net income over the same four quarters: −$578.0M, a −8.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.84.

  • Free cash flow in the twelve months to 30 June 2026: $454.7M, after $142.3M of capital spending.

  • Avantor, Inc. spent $79.6M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 676.5M.

  • Trailing P/E: 14.9×; forward P/E: 16.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Avantor, Inc. employs 13,500 people — $486K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

AVTR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
AVTRAvantor, Inc.$10.1B
80
ALGNAlign Technology, Inc.$11.0B
84
RGENRepligen Corp.$9.5B
93
BAXBaxter International, Inc.$12.8B
91
COOThe Cooper Cos., Inc.$13.3B
81
ATRAptarGroup, Inc.$8.2B
49
SOLVSolventum Corp.$15.6B
89

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Avantor, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AVTR news & analysis

Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research · 4 Sept 2026neutral

Zacks Investment Research compares the year-to-date stock performance of Avantor (AVTR) and BrightSpring Health Services (BTSG) against their medical sector. The report examines how each company has fared relative to its peers so far this year.

Why it matters — AVTR watchers would care because the piece assesses how the company's stock is performing relative to its medical sector peers this year.

Why Is Avantor (AVTR) Up 5.4% Since Last Earnings Report?

Zacks Investment Research · 28 Aug 2026neutral

Avantor reported earnings 30 days ago, and the article considers what may come next for the stock, which has risen 5.4% since that earnings report.

Why it matters — AVTR watchers would care because the piece evaluates how the stock has performed since its latest earnings release and what may follow.

Is Avantor a Buy as Revival Progress Faces Persistent Margin Pressure?

Zacks Investment Research · 25 Aug 2026neutral

Avantor's Revival Program is lifting VWR growth and bioprocessing (BMP) orders, but persistent margin pressure and soft earnings keep the recovery selective despite a higher 2026 outlook, per Zacks Investment Research.

Why it matters — AVTR watchers would care because the report highlights that while the Revival Program is supporting parts of the business and a higher 2026 outlook, ongoing margin pressure and soft earnings mean the recovery remains uneven.

Is Avantor (AVTR) Outperforming Other Medical Stocks This Year?

Zacks Investment Research · 19 Aug 2026neutral

Zacks Investment Research compares the year-to-date performance of Avantor, Inc. (AVTR) and BrightSpring Health Services, Inc. (BTSG) against their medical sector. The piece examines how both companies have fared relative to their industry peers so far this year.

Why it matters — The comparison gives Avantor watchers a benchmark for how the stock is tracking against its medical-sector peers this year.

Are Medical Stocks Lagging Avantor (AVTR) This Year?

Zacks Investment Research · 3 Aug 2026neutral

A Zacks Investment Research report compares the year-to-date performance of Avantor (AVTR) and Johnson & Johnson (JNJ) relative to their sector.

Why it matters — AVTR watchers would care because the piece situates Avantor's performance this year within the broader medical sector context and against a major peer.

FAQ

Frequently asked questions about AVTR stock

What is the AVTR stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Avantor, Inc. have a median 12-month price target of $14, with estimates ranging from $12 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVTR stock a buy right now?

Of the 16 analysts covering Avantor, Inc., 3 rate it a Buy, 12 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Avantor, Inc. 80 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVTR?

As at 8 Sept 2026, Avantor, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (94 of 100).

Will AVTR stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies -4.6% from the last close, and Ticker Nerd's factor model ranks Avantor, Inc. 80 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVTR stock forecast for 2030?

No analyst covering Avantor, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVTR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $19 over the next 12 months.

How has AVTR stock performed over the past year?

Avantor, Inc. returned +16.0% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Avantor, Inc. do?

Avantor, Inc. is a global life science tools and advanced technology company that supplies mission-critical products and services to customers in biopharma, healthcare, education and government, and applied materials industries.

What is the latest news on AVTR?

The most recent item we track (Zacks Investment Research, 4 Sept 2026): "Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?". Zacks Investment Research compares the year-to-date stock performance of Avantor (AVTR) and BrightSpring Health Services (BTSG) against their medical sector. The report examines how each company has fared relative to its peers so far this year.

Company

About Avantor, Inc.

Avantor, Inc. is a global life science tools and advanced technology company that supplies mission-critical products and services to customers in biopharma, healthcare, education and government, and applied materials industries. Its portfolio includes laboratory chemicals, reagents, consumables, equipment, instrumentation, single-use bioprocessing components, and specialty services that support research, development, production, and quality control. The company also provides customized materials and procurement solutions for highly regulated environments, helping laboratories and production teams maintain consistent workflows across the scientific supply chain. Avantor serves customers across the Americas, Europe, Asia, the Middle East, and Africa, with operations centered in Radnor, Pennsylvania.

CEO Mr. Emmanuel Ligner · 13,500 employees · United States · https://www.avantorsciences.com